An interventional study of NEXPOWDER-ENDOHS in Gastro Intestinal Bleeding and Polyps, sponsored by Erasme University Hospital. Recruiting at 12 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-24.
Sponsored by Erasme University Hospital · Not applicable, Interventional, and Prevention
Safety and effectiveness of a new hemostatic system to prevent delayed bleeding after endoscopic resection in a selected high-risk population (NEXPOWDER- ENDOHS).
Indication:
Patients with indication of endoscopy resection by endoscopic mucal resection (EMR) or endoscopic submucosal dissection (ESD) with high risk of delayed bleeding (≥5%).
Hypotheses:
The use of NexpowderTM after upper and lower gastrointestinal ESD or EMR of ≥20mm in high-risk population will prevent and decrease delayed bleeding to less than 5%.
Hypotheses:
The use of NexpowderTM after upper and lower gastrointestinal ESD or EMR of ≥20mm in high-risk population will prevent and decrease delayed bleeding to less than 5%.
Study design:
This is an investigator-initiated, multicentric, international, open-label, non-controlled, prospective study:
Endpoints:
This hypothesis is that the use of NexpowderTM will reduce the rate of DB from 16% (reported rate in the literature) to less than 5% (excepted observed rate during the study).
339 studies on the registry are indexed under Gastrointestinal Hemorrhage; 79 are open to participants now.
This study's planned enrollment of 50 is below the median of 87 across 211 interventional studies indexed under Gastrointestinal Hemorrhage.
Browse Gastrointestinal Hemorrhage studies →Erasme University Hospital is the lead sponsor of 178 studies on the registry; 34 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Standard of care ESD or EMR procedure and application of Nexpowder on the resection site to prevent delayed bleeding.
Device: NEXPOWDER-ENDOHS
Standard of care ESD or EMR procedure and application of Nexpowder on the resection site to prevent delayed bleeding.
Safety in terms of Adverse Events (AE related to Nexpowder)
* number of intraprocedural complications (perforation,...) * number of post-procedure complications (delayed perforation, peritonitis,..)
Time frame: 1 month
Efficacy of Nexpowder in changing the delayed bleeding rate
Decrease the delayed bleeding rate
Time frame: 1 month
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Erasme University Hospital